Reversible airflow obstruction in lymphangioleiomyomatosis

Chest

Volumn 136, Issue 6, 2009, Pages 1596-1603

  Taveira DaSilva, Angelo M ^a   Steagall, Wendy K ^a   Rabel, Antoinette ^a   Hathaway, Olanda ^a   Harari, Sergio ^b   Cassandro, Roberto ^b   Stylianou, Mario ^a   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b San Giuseppe Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARBON MONOXIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; SALBUTAMOL;

ADULT; AGE DISTRIBUTION; AGED; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CLINICAL FEATURE; CONTROLLED STUDY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CAPACITY; LUNG FUNCTION; LYMPHANGIOLEIOMYOMATOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING HABIT; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 73149108212     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-0624     Document Type: Article

References (31)

1. Kitaichi M, Nishimura K, Ito H, et al. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995; 151:527-533
2. Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999; 115:1041-1052
3. Urban TJ, Lazor R, Lacronique J, et al. Pulmonary lymphangioleiomyomatosis: a study of 69 patients. Medicine (Baltimore) 1999; 78:321-337
4. Johnson S. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms. Thorax 1999; 54:254-264
5. Ryu JH, Moss J, Beck GJ, et al. The NHLBI Lymphangio-leiomyomatosis Registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173:105-111
6. Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000; 75:591-594
7. Moss J, Avila NA, Barnes PM, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001; 163:669-671
8. Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001; 164:661-668
9. Taveira-DaSilva AM, Hedin CJ, Stylianou MP, et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2001; 164:1072-1076
10. Yen KT, Putzke JD, Staats BA, et al. The prevalence of acute response to bronchodilator in pulmonary in lymphangioleiomyomatosis. Respirology 2005; 10:643-648
11. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319-338
12. MacIntyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26:720-735
13. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948-968
14. Avila NA, Chen CC, Chu SC, et al. Pulmonary lymphangioleiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology 2000; 214:441-446
15. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126:1867-1874
16. Hayashi T, Fleming MV, Stetler-Stevenson WG, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 1997; 28: 1071-1078
17. Matsui K, Takeda K, Yu ZX, et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000; 124: 267-275
18. Krymskaya VP, Shipley JM. Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am J Respir Cell Mol Biol 2003; 28:546-550
19. Zhe X, Yang Y, Jakkaraju S, et al. Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2003; 28:504-511
20. Ferrans VJ, Yu ZX, Nelson WK, et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch 2000; 67:311-329
21. Sobonya RE, Quan SF, Fleishman JS. Pulmonary lymphangioleiomyomatosis: quantitative analysis of lesions producing airflow limitation. Hum Pathol 1985; 16:1122-1128
22. Burger CD, Hyatt RE, Staats BA. Pulmonary mechanics in lymphangioleiomyomatosis. Am Rev Respir Dis 1991; 143: 1030-1033
23. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140-151
24. Valencia JC, Pacheco-Rodriguez G, Carmona AK, et al. Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2006; 35:40-47
25. Hensley MJ, O'Cain CF, McFadden ER, et al. Distribution of bronchodilation in normal subjects: β-agonist versus atropine. J Appl Physiol 1978; 45:778-782
26. Chhabra SK, Pandey KK. Comparison of acute bronchodilator effects of inhaled ipratropium and salbutamol in bronchial asthma. J Asthma 2002; 39:375-381
27. Guyatt GH, Townsend M, Nogradi S, et al. Acute response to bronchodilators. Arch Intern Med 1988; 148:1949-1952
28. Pellegrino R, Rodarte JR, Brusasco V. Assessing the reversibility of airway obstruction. Chest 1998; 114:1607-1612
29. Galant SP, Morphew T, Amaro S, et al. Value of bronchodilator response in assessing controller naïve asthmatic children. J Pediatr 2007; 151:457-462
30. Hansen JE, Sun XG, Adame D, et al. Argument for changing criteria for bronchodilator responsiveness. Respir Med 2008; 102:1777-1783
31. Chhabra SK. Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD. J Asthma 2005; 42:367-372